SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.26+1.2%Nov 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (30875)4/11/2009 11:27:36 PM
From: Biomaven  Read Replies (2) of 52153
 
>>like the drug coming from Cougar

Their Phase III with survival as the endpoint obviously has real risk, but I could see Abiraterone ending up as the biggest partnership deal in biotech over the next year. It would be a tragedy if they don't hit their survival endpoint and the FDA gives them grief, because the drug is clearly better than existing agents.

MDVN is a year or more behind, but their drug (which goes after the same pathway in a different manner) might be as good or possibly even better.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News